C12N2500/42

METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS

Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.

MEDIUM COMPOSITION AND METHOD FOR CULTURING MESENCHYMAL STEM CELLS
20210324335 · 2021-10-21 · ·

The present invention generally relates to a medium composition and method for culturing mesenchymal stem cells (MSCs), in which the medium comprises an epithelial cell adhesion molecule (EpCAM) peptide, particularly a truncated EpCAM polypeptide containing the extracellular domain (EpEX). It significantly enhances cell proliferation and multipotency of the MSCs.

IDENTIFICATION OF PLATELET ACTIVATING ANTIBODIES
20210325405 · 2021-10-21 ·

Described is a method for identifying pathogenic platelet-activating antibodies in a subject's blood and particularly antibodies implicated in heparin-induced thrombocytopenia (HIT) which comprises the preparation of a platelet releasate from a normal subject's platelets, the combination of the platelet release with a normal subject's platelets, a test subject's blood sample, and analyzing the sample for platelet activation.

CELL CULTURE MEDIA, KITS AND METHODS OF USE
20210309963 · 2021-10-07 ·

Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.

Soft gel systems in modulating stem cell development
11083190 · 2021-08-10 ·

This invention provides gels and matrices having a rigidity in the range of 150-750 Pa, methods of manufacturing same, and method of preserving a mesenchymal stem cell population or studying mesenchymal stem cells, comprising same.

Human iPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

METHOD FOR GENE TRANSFER INTO GAMMA-DELTA TYPE T CELL

The present invention provides a method for efficiently producing highly pure γδT cells introduced with foreign genes by culturing in the presence of IL-7 and IL-15 after stimulating the γδT cells with a bisphosphonic acid ester derivative. When a T cell receptor (TCR) or a chimeric antigen receptor (CAR) is introduced as a foreign gene, γδT cells in which TCR and CAR are functionally expressed can be obtained.

PROCESS
20210108239 · 2021-04-15 ·

The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.

Process

The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.

BIOSYNTHETIC ACTIVITY OF THE ANAPLASMA PHAGOCYTOPHILUM AND EHRLICHIA CHAFFEENSIS PHAGOSOME IN A HOST CELL-FREE MEDIUM
20210024879 · 2021-01-28 ·

Axenic media and methods for growing E. Chaffeensis and/or A. phagocytophilum are provided. In general, the axenic media includes intracellular phosphate buffer (IPB), a carbon source, FBS, a mixture of amino acids, and at least one further component selected from the group consisting of glucose 6-phosphate (G6P), ATP, DTT, GTP, UTP, CTP, and any combination thereof.